<DOC>
	<DOCNO>NCT02547649</DOCNO>
	<brief_summary>This study design assess effect two different formulation pneumococcal polysaccharide vaccine safety immunogenicity V114 healthy adult 50 year age old .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Immunogenicity Two Formulations V114 Healthy Adults 50 Years Age Older ( V114-006 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Good health ; underlie chronic illness must document stable condition Highly unlikely conceive 6 week administration study vaccine Prior administration pneumococcal vaccine History invasive pneumococcal disease know history culturepositive pneumococcal disease Known hypersensitivity vaccine component Known suspect impairment immune function Received systemic corticosteroid &gt; =14 consecutive day complete treatment &lt; =30 day prior study entry , receive systemic corticosteroid exceed physiologic replacement dos within 14 day prior study vaccination Coagulation disorder contraindicate intramuscular vaccination Receives immunosuppressive therapy , include chemotherapeutic agent use treat cancer condition , treatment associate organ bone marrow transplantation , autoimmune disease Received blood transfusion blood product , include immunoglobulin within 6 month receipt study vaccine schedule receive blood transfusion blood product within 30 day receipt study vaccine . Autologous blood transfusion consider exclusion criterion . Participated another clinical study investigational product within 2 month begin time duration current clinical study Breast feed User recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>